AstraZeneca Makes Good On Vow To Build CV Pipeline With AlphaCore Buy
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca’s biologics unit MedImmune acquired AlphaCore Pharma, the developer of an early-stage asset with a novel mechanism for removing cholesterol from the body and raising “good” HDL cholesterol.